Adrian Rawcliffe
2017
In 2017, Adrian Rawcliffe earned a total compensation of $1.5M as Chief Financial Officer at Adaptimmune Therapeutics, a 22% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $199,665 |
|---|---|
| Option Awards | $849,927 |
| Salary | $443,700 |
| Other | $42,556 |
| Total | $1,535,848 |
Rawcliffe received $849.9K in option awards, accounting for 55% of the total pay in 2017.
Rawcliffe also received $199.7K in non-equity incentive plan, $443.7K in salary and $42.6K in other compensation.
Rankings
In 2017, Adrian Rawcliffe's compensation ranked 6,846th out of 14,666 executives tracked by ExecPay. In other words, Rawcliffe earned more than 53.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,846 out of 14,666 | 53rd |
Division Manufacturing | 2,537 out of 5,772 | 56th |
Major group Chemicals And Allied Products | 821 out of 2,075 | 60th |
Industry group Drugs | 635 out of 1,731 | 63rd |
Industry Biological Products, Except Diagnostic Substances | 115 out of 313 | 63rd |
Source: SEC filing on April 27, 2018.
Rawcliffe's colleagues
We found four more compensation records of executives who worked with Adrian Rawcliffe at Adaptimmune Therapeutics in 2017.